Published: Jan 30, 2014The website was developed and will be run jointly by the American Association for the Study of Liver Diseases, the Infectious Diseases Society of America, and the International Antiviral Society-USA.
A panel of 26 experts will keep clinicians on top of HCV treatment options, spokesmen for the three societies told MedPage Today before the site went live.
He told MedPage Today that the site will contain information -- not only on approved uses, but also on specific off-label drug combinations that have not been through the FDA approval process.
That's because it's not realistic to get specific approval for all possible combinations in all possible patient types, Saag said. A major advantage of the new website, he said, is that the panel can look at all the evidence and "craft [regimens that] experts in the field would be using."
Indeed, the first iteration of the site suggests a combination of two new drugs -- simeprevir (Olysio) and sofosbuvir (Sovaldi) -- that is not specifically approved by the FDA, although both drugs are on the market, according to Donald Jensen, MD, of the University of Chicago Medical Center and a spokesman for the liver society.
Continue reading @ MedPage Today or access the complete report by clicking here.
AASLD/IDSA Launches up-to-date guidance for the treatment of hepatitis C
Online Expert Advice for Clinicians Treating Hepatitis C Now Available at HCVguidelines.org
Today, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Society- USA (IAS-USA), announced the launch of a new website, HCVguidelines.org, that will offer up- to-date guidance for the treatment of hepatitis C virus (HCV) infection.
It is estimated that between 3 and 4 million Americans are infected with HCV and have chronic liver disease as a result. The most recent generation of direct-acting antivirals has the potential to cure most patients with HCV. However, the rapid pace of drug development has left medical providers and insurance companies unsure what the optimal treatments are. The guidance provided through HCVguidelines.org will assist clinicians in using these and other treatments in the care of their patients. HCVguidelines.org is the result of an ongoing collaboration between the two medical professional societies and IAS-USA.
New sections will be added, and the recommendations will be updated on a regular basis as new information becomes available. An ongoing summary of "recent changes" will also be available for readers who want to be directed to updates and changes.
The Guidance was developed by a Panel of HCV experts in the fields of hepatology and infectious diseases, using an evidence-based review of information that is largely available to healthcare practitioners, access the complete report by clicking here.
Full Report Menu
Full Report
INTRODUCTION
METHODS
HCV TESTING AND LINKAGE TO CARE
COMING SOON: In Whom and When to Initiate Treatment
INITIAL TREATMENT OF HCV INFECTION IN PATIENTS STARTING TREATMENT
RETREATMENT OF PERSONS IN WHOM PRIOR THERAPY HAS FAILED
COMING SOON: Monitoring Patients Who Are On or Have Completed Therapy
UNIQUE PATIENT POPULATIONS
COMING SOON: Management of Acute HCV Infection
REFERENCES
WEBSITE POLICIES
No comments:
Post a Comment